Choice of treatment options for metastatic hormone-sensitive prostate cancer
The arsenal of available treatments and treatments for metastatic hormone-sensitive prostate cancer (mHRPC) has increased significantly over the past 5 years. Although androgen-preferential therapy (ADT) remains the mainstay of treatment, the addition of docetaxel, abiraterone, enzalutamide, apaluta...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Russo |
| Veröffentlicht: |
Remedium Group LLC
2020-12-01
|
| Schriftenreihe: | Медицинский совет |
| Schlagworte: | |
| Online-Zugang: | https://www.med-sovet.pro/jour/article/view/5941 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|